Breathe Well Live Well
|
MediciNova Reports Fourth Quarter and Full Year 2010 Results
TradersHuddle.com The decrease in research and development expenses primarily related to the completion of the clinical trial evaluating MN-221 at planned escalating doses in patients with severe acute exacerbations of asthma treated in emergency departments in 2009 and … |
View full post on asthma – Google News
|
MediciNova Reports Third Quarter 2010 Results
MarketWatch (press release) The presentations are related to MediciNova's development of MN-221 for potential utility in acute exacerbations of asthma or chronic obstructive pulmonary … |
View full post on asthma – Google News
|
Theravance Reports Third Quarter 2010 Financial Results
MarketWatch (press release) "The RELOVAIR(TM) Phase 3 programs in COPD and asthma are progressing well and have now enrolled over 8000 patients. Last month, preclinical and Phase 2a … |
View full post on asthma – Google News
|
MediciNova Reports Second Quarter 2010 Results
MarketWatch (press release) MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, COPD exacerbations, multiple sclerosis and … |
View full post on asthma – Google News
 Kansas City Star |
Merck pares 2010 forecast, despite beat in quarter
Reuters N) issued a more cautious 2010 profit outlook on Friday and reported disappointing second-quarter sales of its vaccines and Singulair asthma drug, … Merck 2Q Profit Drops 52% On Charges; Key Drug Sales Weaker Merck's profit drops on merger costs, revamp Merck's 2Q net drops on higher costs, charges |
View full post on asthma – Google News
Cumberland Pharmaceuticals Reports First Quarter 2010 Earnings
NASHVILLE, Tenn., May 13 /PRNewswire-FirstCall/ — Cumberland Pharmaceuticals Inc.
Read more on redOrbit